IB
The startup develops exosome-based therapeutics that utilize extracellular vesicles to deliver large therapeutic molecules for conditions such as sepsis and pre-term birth. This technology enables targeted treatment options for inflammatory and metabolic diseases that are difficult to manage with traditional therapies.
Updated 3 months ago
Funding
$39.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Features
- The startup develops exosome-based therapeutics that utilize extracellular vesicles to deliver large therapeutic molecules for conditions such as sepsis and pre-term birth. This technology enables targeted treatment options for inflammatory and metabolic diseases that are difficult to manage with traditional therapies.